Cantor Fitzgerald reissued their buy rating on shares of BioDelivery Sciences International (NASDAQ:BDSI) in a report released on Friday. The firm currently has a $5.00 price objective on the specialty pharmaceutical company’s stock.

“We view BDSI as a Belbuca execution story, and, based on Symphony script data, the company is exceeding its execution goals as well as our expectations. Execution, as well as increased access for Belbuca going into 2019 have increased our conviction that solid execution in 2019 and beyond is likely to continue, which should drive upward earnings revisions and further upside in BDSI stock. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $5.00.”,” the firm’s analyst commented.

A number of other brokerages have also recently issued reports on BDSI. Janney Montgomery Scott reissued a buy rating and set a $5.00 target price on shares of BioDelivery Sciences International in a report on Thursday, January 31st. Zacks Investment Research cut shares of BioDelivery Sciences International from a buy rating to a hold rating in a report on Friday, January 18th. BidaskClub raised shares of BioDelivery Sciences International from a sell rating to a hold rating in a report on Friday, January 11th. Finally, HC Wainwright reissued a buy rating and set a $5.00 target price on shares of BioDelivery Sciences International in a report on Friday, November 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $4.75.

BioDelivery Sciences International stock opened at $4.31 on Friday. BioDelivery Sciences International has a 12 month low of $1.70 and a 12 month high of $4.74. The company has a debt-to-equity ratio of 1.42, a quick ratio of 2.77 and a current ratio of 3.00.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. BioDelivery Sciences International had a negative net margin of 85.93% and a negative return on equity of 141.35%. The business had revenue of $14.16 million for the quarter, compared to analysts’ expectations of $14.21 million. On average, sell-side analysts predict that BioDelivery Sciences International will post -0.59 earnings per share for the current year.

In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the business’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $3.72, for a total transaction of $29,760.00. Following the sale, the director now owns 514,187 shares of the company’s stock, valued at approximately $1,912,775.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark A. Sirgo sold 9,175 shares of the business’s stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $3.57, for a total transaction of $32,754.75. Following the sale, the director now directly owns 506,187 shares in the company, valued at approximately $1,807,087.59. The disclosure for this sale can be found here. Insiders have sold a total of 51,336 shares of company stock worth $189,665 in the last three months. Insiders own 13.26% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of BioDelivery Sciences International by 15.8% in the fourth quarter. BlackRock Inc. now owns 1,388,297 shares of the specialty pharmaceutical company’s stock worth $5,137,000 after purchasing an additional 189,508 shares during the period. Emerald Mutual Fund Advisers Trust bought a new position in shares of BioDelivery Sciences International in the fourth quarter worth $615,000. Emerald Advisers LLC bought a new position in shares of BioDelivery Sciences International in the fourth quarter worth $654,000. Alpha Omega Wealth Management LLC increased its holdings in shares of BioDelivery Sciences International by 3.1% in the fourth quarter. Alpha Omega Wealth Management LLC now owns 156,739 shares of the specialty pharmaceutical company’s stock worth $4,161,000 after purchasing an additional 4,677 shares during the period. Finally, Vanguard Group Inc increased its holdings in shares of BioDelivery Sciences International by 0.3% in the third quarter. Vanguard Group Inc now owns 2,380,456 shares of the specialty pharmaceutical company’s stock worth $6,666,000 after purchasing an additional 7,600 shares during the period. 52.82% of the stock is currently owned by hedge funds and other institutional investors.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Story: How Do Tariffs Affect Trade Balances?

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.